May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab Treatment for Diabetic Macular Edema
Author Affiliations & Notes
  • S. Biester
    Ophthalmology, University Eye Hospital Tuebingen, Tuebingen, Germany
  • F. Ziemssen
    Ophthalmology, University Eye Hospital Tuebingen, Tuebingen, Germany
  • K.-U. Bartz- Schmidt
    Ophthalmology, University Eye Hospital Tuebingen, Tuebingen, Germany
  • F. Gelisken
    Ophthalmology, University Eye Hospital Tuebingen, Tuebingen, Germany
  • Footnotes
    Commercial Relationships S. Biester, None; F. Ziemssen, None; K. Bartz- Schmidt, None; F. Gelisken, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 5028. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Biester, F. Ziemssen, K.-U. Bartz- Schmidt, F. Gelisken; Intravitreal Bevacizumab Treatment for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2007;48(13):5028.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Bevacizumab (Avastin®) has been introduced as a new treatment of different opthtalmologic disorders based on the anti-VEGF effect. The aim of this retrospective study was to evaluate the therapeutic effect of intravitreal bevacizumab in diabetic macular edema.

Methods:: We analysed retrospectively 17 eyes of 15 patients (7 male, 8 female mean age 61.8 years) which were treated with 1.25mg Bevacizumab intravitreally for diabetic macular edema (average of 2.5 injections per eye). Baseline examination included visual acuity, Optical coherence tomography (OCT) (n=17) and fluorescein angiogram (n=16). Mean follow up was 7.8 months (6 -11 months). Two eyes have received focal laser coagulation during follow-up.

Results:: Baseline visual acuity was 20/95 and final visual acuity 20/91 (p=0,59). OCT at baseline showed a central retinal thickness of 543µm (SD +175µm). At the last visit, central thickness of the retina was 464µm (SD +210µm), which was statistically significant (p < 0,05).

Conclusions:: Bevacizumab offers the possibility to treat the leakage in diabetic macular edema. This retrospective study with a mean follow-up of 8 months showed no significant effect of the intravitreal Bevacizumab injections on visual acuity in diabetic macular edema. On the other hand retinal thickness decreased significantly. This suggests that anti-VEGF therapy may have a place in the treatment of diabetic macular edema. Further studies are necessary to identify the subgroups of diabetic patients who may respond better to the intravitreal anti-VEGF therapy.

Clinical Trial:: University Tuebingen

Keywords: diabetic retinopathy • edema • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×